The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

The label expansion is based on results from a trial that showed Spravato provided improvements over placebo in all 10 of the categories in the Montgomery-Asberg Depression Rating Scale (MADRS).

Spravato, okayed for stand-alone use among adults ... An estimated 21 million (2.10 crore) adults in the US have MDD, making it one of the most common psychiatric disorders, the US pharmaceutical ...

On day 28 of the trial, patients taking Spravato exhibited numerical improvements for all 10 items on the Montgomery-Asberg Depression Rating Scale (MADRS). After 4 weeks, 22.5% of patients taking ...

7.6% of patients in the placebo at week 4. Spravato demonstrated improvements across all 10 MADRS items at day 28, and, as a standalone treatment, maintained a safety profile consistent with ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...